Opus Genetics (IRD) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Opus Genetics (NASDAQ: IRD) in the last few weeks:

• 8/16/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/11/2026 – Opus Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/8/2026 – Opus Genetics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/7/2026 – Opus Genetics had its price target lowered by Royal Bank Of Canada from $10.00 to $9.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Opus Genetics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 7/17/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Opus Genetics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/6/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $13.00 price target on the stock.
• 7/6/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.

Insider Activity at Opus Genetics

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the transaction, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 29,331 shares of company stock valued at $86,629. Company insiders own 11.70% of the company’s stock.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.